ntributed to the development of several clinical candidates including templates present in Iressa®, Zactima® and other medicines. Dr. Kocis also led the development of company-wide criteria for medicinally relevant compounds and the development of AstraZeneca compound profilers for research programs, clinical candidates and the corporate compound collection. Previously, at Zeneca Pharmaceuticals, he spearheaded modern medicinal chemistry together with the development of proprietary chemical technologies and chemical libraries that were industrialized across a number of therapeutic areas. Dr. Kocis is one of the pioneers of combinatorial chemistry and of the concept of chemical libraries, especially libraries exploiting medicinally relevant chemical space. He was instrumental in building Selectide’s combinatorial che

 ntributed to the development of several clinical candidates including templates present in Iressa®, Zactima® and other medicines. Dr. Kocis also led the development of company-wide criteria for medicinally relevant compounds and the development of AstraZeneca compound profilers for research programs, clinical candidates and the corporate compound collection. Previously, at Zeneca Pharmaceuticals, he spearheaded modern medicinal chemistry together with the development of proprietary chemical technologies and chemical libraries that were industrialized across a number of therapeutic areas. Dr. Kocis is one of the pioneers of combinatorial chemistry and of the concept of chemical libraries, especially libraries exploiting medicinally relevant chemical space. He was instrumental in building Selectide’s combinatorial che